Loading news...
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company.
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people with highly active relapsing forms of multiple sclerosis (RMS). The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Düsseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as ≥2 relapses in the year prior and ≥1 gadolinium-enhancing (Gd+) T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity (NEDA-3), with BRIUMVI compared to teriflunomide. Additional details from the publication are included below.
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026 annual meeting, being held April 18 - 22, 2026, in Chicago, Illinois. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progres.
TG Therapeutics (NASDAQ: TGTX) executives highlighted rapid revenue growth for BRIUMVI in 2025, expanding adoption in relapsing multiple sclerosis (RMS), and multiple upcoming clinical and regulatory catalysts during the company's fourth-quarter and year-end 2025 earnings call. BRIUMVI revenue growth and 2026 outlook Chairman and CEO Michael Weiss said 2025 was a "defining year," with the company
TG Therapeutics remains a "Strong Buy," driven by robust BRIUMVI revenue growth and ambitious expansion initiatives. The company reported $594 million in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850 million in 2026. Key catalysts include the phase 3 ENHANCE study (consolidated dosing) and a self-administered subcutaneous BRIUMVI, both targeting significant market segments.
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.15 per share a year ago.
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company.
Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below.
Hussman Stratgic Advisors sold 126,000 shares of TG Therapeutics. The fund no longer holds any shares.
Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f
Shares of TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to